Navigation Links
ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
Date:8/5/2010

8.66 versus 15.4 +/- 8.41 injections, p<0.001) and the total number of days of swelling (10.1 +/- 10.73 versus 29.6 +/- 16.9 days; p<0.001).

Cinryze Acute Treatment Study

According to the authors, subjects experiencing attacks of moderate or severe intensity involving the abdomen, face, or external genitalia were eligible for randomized treatment. Eligible subjects were then randomized to receive either Cinryze (1000 U) or saline by intravenous push over 10 minutes. After 60 minutes, a second injection of the same study drug was administered if the subject had not reported symptoms to be either "absent" or "better" at the site of the most severe symptoms which had been designated as the "defining site".  Symptom severity was assessed every 15 minutes starting from the initial injection and continuing until the subject reported "unequivocal relief," defined as three consecutive reports of improvement at the defining site. If four hours had elapsed without "unequivocal relief," trial assessments were discontinued and rescue therapy with open-label Cinryze was offered.  

The primary end point was the time from study drug administration until the onset of unequivocal relief of symptoms at the defining site. Secondary efficacy measures included percentage of subjects who had unequivocal relief within four hours following treatment; time to complete resolution of the attack; and effects of treatment on C1 inhibitor antigenic and functional levels and C4 levels.  Safety of Cinryze was also assessed.

Seventy-one eligible subjects were randomized into this study, 36 to Cinryze and 35 to placebo. After completion of study treatment, three subjects (one randomized to Cinryze and two randomized to placebo) were judged by an independent, blinded expert to have experienced episodes that were not true attacks of angio
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Abaxis, Inc. (NasdaqGS: ABAX ... systems, today reported financial results for the second fiscal ... overview: , Revenues of $53.9 million, up 18% ... of $0.24, up 33% over last year,s comparable quarter. ... Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, up ...
(Date:10/22/2014)... Mass. , Oct. 22, 2014 InVivo ... Cambridge, MA is revolutionizing spinal cord injury ... has been shown to outperform in tissue regrowth in ... the scaffold.  Made from an FDA approved polymer, the ... making it harmless to the human body. NVIV has ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 /PRNewswire/ ... they have entered into a license and collaboration ... target cancers. PhosImmune possesses technology for ... surfaces of tumor cells in association with HLA ... proteins that play a role in malignancy, are ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... April 4, 2011 CarePoint Partners ... Association Annual Conference in Orlando, Florida that it ... infusion therapies including antibiotics, IVIG, nutrition, the associated ... with locations in North Miami and Tampa. This ...
... (Nasdaq: VVUS ) today announced long-term data that ... years showed reductions in blood pressure and the use of ... significant reductions in weight loss as compared to those in ... data – additional results from the SEQUEL study – were ...
Cached Medicine Technology:CarePoint Partners Expands Florida Footprint With Acquisition of Infusion Technologies 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 3
(Date:10/22/2014)... 2014 Although there are only 24 hours in ... people who have trouble finding time within their busy schedules for ... long periods of time to get in shape. Here are five ... the go. , Change Up Your Commute , Consider riding ... add some exercise into your daily routine. If you must use ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Two sisters in ... heart damage. Ilina and Medha Krishen use electronic ... sounds of trouble in breathing patterns or heartbeats. ... in Michigan, wanted to find a way to detect ... pollutants. Using an electronic stethoscope, Ilina recorded one breath ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... Infinity Business Systems ( www.ibsfl.com ) is proud ... ( www.vitil.com ) private business services, providing advanced ... Infinity Business Systems has over 40 employees ... Southwest Florida markets. IBS services include IT ...
... An attorney, a psychologist, and a past,surrogate will ... free teleseminar,on July 31 designed to demystify gestational ... of Carrying Someone,Else,s Baby" aims to help prospective ... role. The panel of experts will,discuss issues ranging ...
... treatable diseases around,the world, Statement by Dr. ... TOYAKO, Japan, July 8 "The worldwide,pharmaceutical industry ... Drugs for Neglected Diseases initiative (DNDi) in calling ... diseases as a global health threat,and a major ...
... the key organ in the response to stress. Brain reactions ... stressful for us, and regulate the stress responses that can ... brain and lead into depression: Environmental stressors related to job ... major life events such as trauma or abuse amongst the ...
... 8 Kewaunee Scientific,Corporation (Nasdaq: KEQU ) ... Russell,Microcap Index after the Russell Investment Group reconstituted ... on June 27, 2008., Russell indexes are ... both index funds and as benchmarks for passive,and ...
... factor predisposing to suicide, and more than half ... have suffered from depression. Unfortunately, depression is still ... attempt. Antidepressive drugs represent the cornerstone of treatment ... somewhat controversial over the last few years due ...
Cached Medicine News:Health News:Infinity Business Systems of Tampa Expands Into Sarasota / Bradenton 2Health News:Infinity Business Systems of Tampa Expands Into Sarasota / Bradenton 3Health News:Free Teleseminar Explores Surrogacy Requirements, Rights, Rewards 2Health News:Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases 2Health News:Kewaunee Scientific Added to Russell Microcap Index 2
The ZEPHIR Anterior Cervical Plate System is the lowest profile plate clinically available....
... 16 is Philips premium 16-slice CT scanner. ... to automatically delivering high quality, advanced results, the ... a platform that has been the most popular ... comprehensive organ assessment literally within seconds, and with ...
... The PLIF instrument set consists ... conjunction with nerve root protectors, for ... rectangular allograft bone blocks of the ... proper channel preparation which is important ...
... Dilation Port enables the surgeon to perform ... approach using step dilation. Using a series ... aside, creating space for a custom-sized working ... surgeon to operate with a traditional surgical ...
Medicine Products: